Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Asset Writedowns and Impairment (2020 - 2022)

Innate Pharma posted quarterly Asset Writedowns and Impairment of -$41830.1 for Q4 2022, up 99.92% on a QoQ basis from -$51.9 million in Q4 2020.

Innate Pharma (IPHA) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$41830.1 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -41,830.14
Dec 31, 2022 -41,830.14
Dec 31, 2020 -51.90 Mn
Dec 31, 2020 -51.90 Mn